1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate;2-phenylbutanoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate;2-phenylbutanoic acid
• 化学式: C43H46N6O8
• 分子量: 774.9
• InChiKey: ITGMNRKOGLVJIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.58
• 重原子数：
  57
• 可旋转键数：
  16
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  181
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• METHODS FOR DETERMINING PERSONALIZED TREATMENT COMPOSITIONS FOR PROSTATE CANCER AND BREAST CANCER
  申请人：Caldera Health Limited

  公开号：EP2870480A1

  公开（公告）日：2015-05-13
• US8784795B2
  申请人：——

  公开号：US8784795B2

  公开（公告）日：2014-07-22
• [EN] METHODS FOR DETERMINING PERSONALIZED TREATMENT COMPOSITIONS FOR PROSTATE CANCER AND BREAST CANCER<br/>[FR] MÉTHODES DE DÉTERMINATION DE COMPOSITIONS DE TRAITEMENT PERSONNALISÉ CONTRE LE CANCER DE LA PROSTATE ET LE CANCER DU SEIN
  申请人：CALDERA HEALTH LTD

  公开号：WO2014007661A1

  公开（公告）日：2014-01-09

  The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering a combination of at least two components selected from immune cell activating agents, such as GM-CSF, and antigen display enhancing agents, such as ketoconazole. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period.